Bioptimus, an AI company based in Paris, has raised $41M in its latest funding round, bringing its total funding to $76M. This comes less than a year after its initial seed round, signaling strong investor confidence. The funding, led by Cathay Innovation, will fuel Bioptimus’s mission to transform biological research with its groundbreaking AI model.
A model that simulates biology
Unlike traditional research that isolates different biological components, Bioptimus aims to break down these barriers. Their model integrates data from various biological scales—molecules, cells, tissues, and organisms—creating a holistic view of biology. CEO Jean-Philippe Vert likens their model to the “GPT of biology,” except it simulates biology instead of generating text. This innovation promises to enhance research in fields like medicine, biotechnology, and even cosmetics, enabling more precise predictions of disease outcomes, responses to treatments, and drug designs.
Breakthroughs expected
The company’s first major success, the H-Optimus-0 model for pathology, already outperforms others in independent benchmarks, including studies at Harvard and the University of Leeds. With the new funding, Bioptimus plans to further refine its platform, develop strategic partnerships, and expand its datasets, setting the stage for major breakthroughs in biological research and beyond.